News

July 15 () - Shares of Celcuity fell about 8% in premarket trading on Wednesday, as the delayed commercial launch ‌of its newly approved breast cancer drug and treatment-tolerability ‌concerns overshadowed the company's first U. Food and Drug Administration on ​Tuesday approved gedatolisib, branded as Revtorpyk, for certain patients with advanced breast cancer whose tumors do not carry a PIK3CA mutation.

Just one day after glowing reviews, a surprise revenue warning sent the stock into a tailspin and brought lawyers to the door.

Still, shares fell by nearly 20% after the company revealed a delay in the coming launch of Revtorpyk. Details in the drug’s prescribing information surprised some analysts, too.

Alphabet unit Google on Wednesday urged Europe's top court to dismiss EU antitrust regulators' appeal ‌against a lower court ruling that scrapped a €1.49 billion ($1.7 billion) fine, saying ‌the regulators' arguments were flawed. The dispute reached the Court of Justice of the European Union ​after regulators appealed a 2024 General Court ruling that annulled the fine imposed on Google in 2019. The lower court cited errors in the European Commission's assessment of the case.

The primary reason for the 12-state lawsuit is that a Paramount-WBD combination would curb entertainment content and distribution, putting the TV/movie marketplace into fewer hands. What's the fallout?

FDA grants full approval to Eli Lilly's selpercatinib (Retevmo) for a wider group of adult and pediatric patients with RET fusion solid tumors. The decision shifts selpercatinib from accelerated to traditional approval and broadens its labeled use across multiple tumor types. The update reinforces Eli Lilly's (NYSE:LLY) position in oncology and opens new commercial and clinical avenues for the drug. Eli Lilly, known for its oncology and biopharma portfolio, now has a fully approved RET...

The product is expected to be OpenAI’s first physical AI device and a crucial milestone as the company moves forward with its IPO plans.

Boston Scientific recently initiated several voluntary Class II recalls of its CRE and CRE Pro Wireguided endoscopy devices worldwide due to potential sterile breaches in packaging, affecting tens of thousands of units across multiple size ranges. The recalls underscore the operational and regulatory risks inherent in Boston Scientific’s expanding minimally invasive device portfolio, especially as it integrates recent acquisitions and scales global distribution. We’ll now examine how these...

Pfizer, trading as NYSE:PFE, received FDA approval for a platinum-free Padcev-Keytruda regimen in muscle-invasive bladder cancer. The regimen is approved as both neoadjuvant and adjuvant therapy for adult patients, regardless of cisplatin eligibility. This decision expands use of the combination across a broader bladder cancer population and introduces a new treatment option. For investors watching Pfizer at a share price of $24.25, this approval adds a fresh development to the oncology...

The U.S. Department of Justice has expanded an antitrust investigation to include UnitedHealth Group's Claritev unit. The Claritev review is part of broader DOJ scrutiny of healthcare industry practices and market competition. This development adds a fresh layer of regulatory attention for UnitedHealth Group (NYSE:UNH) beyond routine oversight. UnitedHealth Group, one of the largest managed care and healthcare services companies in the U.S., spans insurance, care delivery, and data-driven...

OpenAI has issued another statement on the lawsuit, this time suggesting it lacks merit.

Apple seeks damages and other legal remedies that could slow OpenAI's device development and hiring.

OpenAI says it takes Apple’s complaint seriously but questions whether the allegations have any merit.

Gedatolisib, in-licensed from Pfizer in 2021, is Celcuity’s sole late-stage asset.

There’s no sugarcoating it; getting laid off is awful. But if you've been following the news, it feels like tech workers are being laid off left and right. Here’s what one Reddit user, who was recently laid off from an account executive role at a tech company, had to say on the r/Layoffs subreddit: ...

This deal could seriously harm movie theatres.

Eli Lilly and Company (LLY) on Tuesday received traditional approval from the US Food and Drug Admin

(Updates with Claritev's response in the fourth paragraph.) The US Justice Department recently se

Hachette, Cengage, Elsevier, and other publishers allege that Google trained its AI on copyrighted works without the necessary permissions.

(Update with the Justice Department's response to a request for comment in the third paragraph.)

Plaintiffs allege Meta's AI-assisted evaluation process was discriminatory.

BIIB secures FDA approval for Leqembi Iqlik, letting early Alzheimer's patients start with a weekly at-home autoinjector instead of biweekly IV infusions.

Apple's lawsuit against OpenAI shows how important AI devices will be for the iPhone maker.

Stock Market Today: The Dow Jones index dropped Tuesday ahead of the June CPI inflation report. IBM stock plunged 23% on earnings.

Apple hit an all-time stock high after it filed one of its most aggressive lawsuits in years, and the market barely flinched. That disconnect between price and risk is exactly what most investors are not pricing in right now.

Carr expressed his views on the Paramount-Warner Bros. Discovery merger, antitrust concerns and Disney’s DEI-related investigations.

Apple almost never sues, so when Tim Cook personally greenlit a complaint accusing OpenAI of stealing trade secrets and smuggling hardware prototypes out the door, Wall Street and Silicon Valley both took notice. The question now is whether the case disrupts OpenAI's IPO plans before a single share is priced.

‘The bad blood between Apple and OpenAI plays into Google’s hands,’ says Paul Meeks, head of technology research at Freedom Capital Markets.

Costco Wholesale is facing a proposed class-action lawsuit alleging that an exclusive protein powder sold in its warehouses contained undisclosed heavy metals. The complaint claims Costco failed to warn customers about potential contamination in a widely marketed product. The case raises questions about Costco's product quality controls and the strength of its consumer trust. For investors watching Costco Wholesale, ticker NasdaqGS:COST, the focus has often been on its membership model and...

Public dispute escalates as Apple sues OpenAI and Musk renews criticism while defending SpaceX's AI infrastructure plans.